ivy rx semaglutide Wegovy®

After discontinuation, there was a pronounced rebound in weight (MD=4.13 kg, 95% CI: 1.60 to 6.65), BMI (MD=0.84 kg/m2, 95% CI: 0.37 to 1.32), WC (MD=3.64 cm, 95% CI: 2.27 to 5.01), and HbA1c (SMD=0.69, 95% CI: 0.50 to 0.89)

Discover the optimal semaglutide dosage for effective weight loss

.

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

In this review, the GLP-1/GLP-1R system implicated in diabetic endothelial dysfunction and related autophagy mechanism underlying the pathogenesis of diabetic vascular complications are briefly presented